To include your compound in the COVID-19 Resource Center, submit it here.

Revlimid lenalidomide: Additional Phase II data

Additional data from a Phase II trial in 93 evaluable patients with newly diagnosed indolent B cell NHL showed that Revlimid plus rituximab led

Read the full 248 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE